Patrick Doyle
Chief Executive Officer
Mr. Patrick Doyle serves as the Chief Executive Officer of KBio and brings more than 20 years of leadership experience with pharmaceutical and biotech companies around the world. He is a proven leader with a track record of innovation and talent development and a deep knowledge of pharmaceutical development, M&A, and pathways to successful commercialization. Mr. Doyle most recently served as Chief Executive Officer of Stelexis Therapeutics in New York, a biotech company with a proprietary platform to discover and selectively target precancerous stem cells. He has also been responsible for multiple financings and strategic exits of biotech of various stages of development. During his Big Pharma tenure, Mr. Doyle led an international group of corporate development executives in several large alliances in Asia.
Mr. Doyle is originally from the UK and has worked in the UK, Switzerland, and the US (California, and more recently, in New York City). He has a BSc in pharmacology from the University of Sunderland.